- $85.37m
- -$70.53m
- 59
- 50
- 25
- 41
Annual income statement for XBiotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 44 | 18.4 | 4.01 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 9.45 | 12.6 | 3.36 | 0 | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 62.3 | 43.5 | 38.5 | 37.5 | 42.5 |
| Operating Profit | -18.3 | -25.1 | -34.5 | -37.5 | -42.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.8 | -25.5 | -33.6 | -24.3 | -38.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -11.2 | -17.4 | -32.9 | -24.6 | -38.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.2 | -17.4 | -32.9 | -24.6 | -38.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.2 | -17.4 | -32.9 | -24.6 | -38.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.364 | -0.58 | -1.08 | -0.807 | -1.26 |
| Special Dividends per Share |